Gold-Enhanced Lanthanide Nanomedicine for Near-Infrared Photodynamic Therapy
- 20 July 2025
- journal article
- review article
- Published by American Chemical Society (ACS) in Langmuir
Abstract
Cancer remains a major global health challenge due to its high morbidity and mortality rates. Traditional treatments, such as surgery, radiotherapy, and chemotherapy, have some clear limitations, which is why there is a growing need for innovative therapeutic modalities. One precise targeting of tumors with few side effects can be achieved through a promising modality called photodynamic therapy (PDT). PDT is a noninvasive cancer treatment that uses photosensitizers to produce cytotoxic species that selectively kill cancer cells under light exposure. In recent years, a variety of nanoparticles (NPs) have been developed. Among them, gold-doped lanthanide NPs (Au-Ln NPs) stand out as a significant advancement in PDT due to the integration of the surface plasmon resonance (LSPR) properties of AuNPs and upconversion (UC) luminescence of Ln NPs. In this perspective, we review various synthesis methods for upconversion nanoparticles (UCNPs) and gold nanoparticles (AuNPs), highlighting their integration into multifunctional Au-Ln NPs for enhanced PDT. By using near-infrared (NIR) light, Au-Ln UCNPs can penetrate deep into tissues, making them particularly effective for treating deeply seated tumors. However, the synthesis of Au-Ln NPs comes with its own challenges. The main challenges include the uniform distribution of gold doping, the control of the particle size and shape, and the reproducibility as well as scalability. Overcoming these challenges for controlled synthesis and enhanced PDT will be critical. Correspondingly, their PDT applications are discussed in vitro and in vivo. Lastly, the current challenges, limitations, and future prospects will be explored.Keywords
Funding Information
- National Natural Science Foundation of China (51861145309, 51971029, 52471259)
- National Science and Technology Major Project (2018ZX10301201)
- Henan Province (39080070)
- Hangzhou Ruidi Biotechnology Company Ltd. (39080070)
This publication has 251 references indexed in Scilit:
- Nanomedicine2024
- Rare Earth Luminescent Nanomaterials and Their Applications2022
- Clinical Development of Metal Complexes as Photosensitizers for Photodynamic Therapy of CancerAngewandte Chemie International Edition, 2021
- Light Irradiation of Gold Nanoparticles Toward Advanced Cancer TherapeuticsAdvanced Therapeutics, 2019
- Phase‐Change Materials Based Nanoparticles for Controlled Hypoxia Modulation and Enhanced PhototherapyAdvanced Functional Materials, 2019
- Mechanistic investigation of phytochemicals involved in green synthesis of gold nanoparticles using aqueous Elaeis guineensis leaves extract: Role of phenolic compounds and flavonoidsBiotechnology and Applied Biochemistry, 2019
- Light‐Triggered In Situ Gelation to Enable Robust Photodynamic‐Immunotherapy by Repeated StimulationsAdvanced Materials, 2019
- Er3+ Sensitized 1530 nm to 1180 nm Second Near‐Infrared Window Upconversion Nanocrystals for In Vivo BiosensingAngewandte Chemie, 2018
- Cypate‐Conjugated Porous Upconversion Nanocomposites for Programmed Delivery of Heat Shock Protein 70 Small Interfering RNA for Gene Silencing and Photothermal AblationAdvanced Functional Materials, 2016
- Chitosan Films Doped with Gold Nanorods as Laser‐Activatable Hybrid BioadhesivesAdvanced Materials, 2010